ESR1 and breast cancer: Overall, these data suggest that ESR1 mutations occur more frequently in the advanced setting than in early BC, that the frequency is higher in more heavily pre-treated endocrine-resistant patients, and that treatment with aromatase inhibitors may exert a selective pressure favoring the expansion of ESR1-mutated clones.